Surging sales of Johnson & Johnson’s prescription medicines and the rebound of its recall-plagued consumer health business lifted fourth-quarter profit 19 percent.
The health care giant also enjoyed a $707 million tax benefit from writing off money-losing subsidiary Scios.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.